Hospital pharmacist support for people starting oral cancer treatment
Evaluation of the Impact of the Clinical Pharmacist in the Initiation and Follow-up of Oral Therapies in Oncology.
NA · Polyclinique Lyon Nord · NCT06980012
This will test whether a hospital pharmacist's consultation and follow-up at the start of oral cancer therapy help patients stick to their medication and manage side effects.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 90 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Polyclinique Lyon Nord (other) |
| Locations | 1 site (Rillieux-la-Pape) |
| Trial ID | NCT06980012 on ClinicalTrials.gov |
What this trial studies
This is a prospective interventional study that compares pharmaceutical monitoring at therapy initiation with usual care for patients starting oral cancer treatment. The intervention includes a pharmaceutical consultation and ongoing follow-up, coordinated between the hospital pharmacy and the patient's community pharmacy. The primary outcome is medication adherence measured by the Girerd questionnaire, with additional monitoring of side-effect detection and management. The trial is conducted at Polyclinique Lyon Nord and enrolls patients with solid tumors beginning oral anticancer therapy within 30 days.
Who should consider this trial
Good fit: Adults with a solid tumor (non-hematologic) who are starting an oral anticancer treatment within the past 30 days and will receive their medication from a community pharmacy are the intended participants.
Not a fit: Patients with hematologic malignancies, those already on oral treatment for more than 30 days, residents of institutions, or those whose treatment is not dispensed in a pharmacy are unlikely to benefit from this approach.
Why it matters
Potential benefit: If successful, the intervention could improve medication adherence, enable earlier detection and better management of side effects, and improve coordination with community pharmacies.
How similar studies have performed: Pharmacist-led counseling has improved adherence in other chronic disease settings and some oncology programs, but evidence specifically for oral cancer therapy is still limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patient suffering from an oncological pathology (excluding hematological malignancies) * Initiation of a specific treatment in the context of an oncological pathology: oral therapy treatment taken at home in oncology (which may follow surgery, radiotherapy or other in-patient treatments). * Patient who has not yet started treatment or who has started treatment less than 30 days * Patient with continuation of oral therapy dispensed in pharmacies Exclusion Criteria: * Patients suffering from hematological malignancies * Patient living in an institution or hospital * Patient under treatment for more than 30 days * Patient undergoing treatment other than oral therapy (venous or subcutaneous anticancer treatment) * Patient whose treatment after initiation is not dispensed in a pharmacy
Where this trial is running
Rillieux-la-Pape
- Polyclinique Lyon Nord — Rillieux-la-Pape, France (RECRUITING)
Study contacts
- Study coordinator: Marion Mandon, PhD
- Email: mmandon@vivalto-sante.com
- Phone: +33678277672
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Neoplasm